Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing.

ABSTRACT:

Background

The Molecular International Prognostic Scoring System (IPSS-M) has improved the prediction of clinical outcomes for myelodysplastic syndromes (MDS). The Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS), based on classical clinical parameters, has outperformed the IPSS, revised version (IPSS-R). For the first time, we validated the IPSS-M and other molecular prognostic models and compared them with the established IPSS-R and AIPSS-MDS models using data from South American patients.

Methods

Molecular and clinical data from 145 patients with MDS and 37 patients with MDS/myeloproliferative neoplasms were retrospectively analyzed.

Results

Prognostic power evaluation revealed that the IPSS-M (Harrell's concordance [C]-index: 0.75, area under

SUBMITTER: Lincango M 

PROVIDER: S-EPMC11609712 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature